James M. Roach Net Worth

The estimated Net Worth of James M. Roach is at least $1.19 Milhão dollars as of 21 November 2016. James Roach owns over 1,091 units of Pulmatrix Inc stock worth over $291,339 and over the last 17 years James sold PULM stock worth over $896,514.

James Roach PULM stock SEC Form 4 insiders trading

James has made over 71 trades of the Pulmatrix Inc stock since 2010, according to the Form 4 filled with the SEC. Most recently James sold 1,091 units of PULM stock worth $14,914 on 21 November 2016.

The largest trade James's ever made was exercising 50,000 units of Pulmatrix Inc stock on 29 March 2015 worth over $370,500. On average, James trades about 2,158 units every 31 days since 2008. As of 21 November 2016 James still owns at least 155,381 units of Pulmatrix Inc stock.

You can see the complete history of James Roach stock trades at the bottom of the page.

What's James Roach's mailing address?

James's mailing address filed with the SEC is 675 WEST KENDALL ST, , CAMBRIDGE, MA, 02142.

Insiders trading at Pulmatrix Inc

Over the last 9 years, insiders at Pulmatrix Inc have traded over $4,537,500 worth of Pulmatrix Inc stock and bought 290,998 units worth $2,002,066 . The most active insiders traders include Steven Gillis, Terrance Mcguire, eInnovative Sciences, Inc. O.... On average, Pulmatrix Inc executives and independent directors trade stock every 92 days with the average trade being worth of $521,728. The most recent stock trade was executed by David L. Hava on 20 March 2017, trading 2,263 units of PULM stock currently worth $5,001.

What does Pulmatrix Inc do?

pulmatrix is a clinical stage biotechnology company with an inhaled dry powder platform advancing a new generation of inhaled therapeutics. the platform, called isperse (inhaled small particles easily respirable and emitted), represents a new paradigm in inhaled drug delivery based on unique properties: dense, high drug load engineered particles with highly efficient dispersibility and delivery to the airways. the isperse powders can be used with an array of dry powder inhaler technologies and can be formulated with virtually any drug substance.

Complete history of James Roach stock trades at Momenta Pharmaceuticals e Pulmatrix Inc

Pulmatrix Inc executives and stock owners

Pulmatrix Inc executives and other stock owners filed with the SEC include:

• Teofilo Raad,
  President, Chief Executive Officer, Director
• Teofilo David Raad MBA,
  Pres, CEO & Director
• Teofilo David Raad,
  Pres, CEO & Director
• Michelle S. Siegert,
  VP of Fin. and Principal Financial & Accounting Officer
• Michelle Siegert,
  Vice President - Finance
• Michael Higgins,
  Independent Chairman of the Board
• Timothy McCarthy,
  Investor Relations
• Amit Munshi,
  Independent Director
• Mark Iwicki,
  Independent Director
• Rick Batycky,
  Independent Director
• Christopher Cabell,
  Director
• Todd Bazemore,
  Director
• Dr. Margaret M. Wasilewski M.D.,
  Chief Medical Officer
• Peter Ludlum CMA, MBA,
  Interim CFO and Principal Accounting & Financial Officer
• Dr. Robert S. Langer Jr., Ph.D., Sc.D., SCD,
  Founder & Member of Scientific Advisory Board
• David J. Maki J.D.,
  Advisor
• Dr. Alexander M. Klibanov Ph.D.,
  Founder
• Prof. David A. Edwards,
  Founder & Member of Scientific Advisory Board
• Dr. Robert S. Langer Jr.,
  Founder & Member of Scientific Advisory Board
• Steven Arch Venture Fund Vi...,
  
• David L. Hava,
  Chief Scientific Officer
• Matthew L Sherman,
  Director
• William E. Duke,
  Chief Financial Officer
• Robert W. Clarke,
  Chief Executive Officer
• Steven Gillis,
  Director
• Kurt Graves,
  Director
• Terrance Mcguire,
  Director
• Scott M Rocklage,
  Director
• Richard P. Batycky,
  Director
• Venture Fund Vii, L.P.Arch ...,
  
• James M. Roach,
  Chief Medical Officer
• Terrance Flint Jonathan A P...,
  
• Innovative Sciences, Inc. O...,
  10% owner
• David Maki,
  Director
• Anand Varadan,
  Director
• Margaret Wasilewski,
  Chief Medical Officer